VIDEO: Adjuvant ribociclib shows efficacy in HR-positive, HER2-negative early breast cancer
Click Here to Manage Email Alerts
In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.
The study showed the efficacy of adjuvant ribociclib (Kisqali, Novartis) plus nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.
“We have 4-year [invasive DFS] estimates and there’s about an absolute difference of 4.9% between patients who did and did not receive ribociclib,” Lin told Healio.
Furthermore, this benefit was seen in patients with stage II, stage III and node-negative disease, Lin said.
Lin added that soon after ESMO, the FDA approved the use of adjuvant ribociclib in hormone receptor-positive, HER2-negative patients with stage II or stage III disease at high risk for recurrence.
“I think that these data will further bolster the use of ribociclib in the adjuvant setting,” Lin said.
Reference:
- Fasching PA, et al. Abstract LBA13. Presented at: European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.
- Loi S, et al. Abstract 235MO. Presented at: European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.
Collapse
Click Here to Manage Email Alerts